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Table 1
High-risk indications for 23-valent PPSV immunization: persons 2 through 64 years
of age.1
• Chronic cardiovascular disease (e.g., congestive heart failure,
cardiomyopathy)
• Chronic pulmonary disease (e.g., chronic obstructive pulmonary
disease, emphysema)
• Chronic liver disease (e.g., cirrhosis, disease resulting from alcohol
abuse)
• Diabetes mellitus
• Asthma with chronic bronchitis, emphysema, long-term use of
corticosteroids
• Functional or anatomic asplenia (e.g., sickle cell disease, splenectomy)
• Chronic cerebrospinal ﬂuid leaks (from congenital lesions, skull
fractures, neurosurgical procedures)
• Immunocompromising conditions (e.g., congenital immunodeﬁciency,
AIDS, symptomatic or asymptomatic HIV infection, leukemia,
lymphoma, Hodgkin’s disease, multiple myeloma, generalized
malignancy, chronic renal failure, nephrotic syndrome, organ or bone
marrow transplantation)
• Use of certain therapies (e.g., immunosuppressive chemotherapy,
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Ralkylating agents, antimetabolites, systemic corticosteroids)
• Residents of nursing homes or long-term care facilities
PSV=pneumococcal polysaccharide vaccine.
ization Practices1 recommends a single dose of the 23-valent
PSV for adults ≥65 years of age who have not previously been
accinated or whose vaccination status is unknown, and for
ersons 2 through 64 years of age with certain high-risk conditions
Table 1). Routine revaccination is not recommended; however,
single revaccination with 23-valent PPSV is recommended for
dults ≥65 years of age who have not received the vaccine within
years and who were ﬁrst vaccinated before age 65. Revaccination
s also recommended for persons 2 through 64 years of agewho are
t the highest risk for serious pneumococcal disease (see Table 1),
rovided that 5 years have elapsed since the initial vaccinationwas
eceived.1
A recent study4 evaluated the safety and tolerability of 13-
alent pneumococcal conjugate vaccine (PCV13) administered
oncomitantly with the trivalent inactivated inﬂuenza vaccine
TIV) and the immunogenicity of the combination versus either
iven alone. Results of the study showed that the immune
esponse of PCV13+TIV was comparable to PCV13 or TIV given
lone. Subjects aged ≥65 years (n =1160) were randomized to
eceive PCV13+TIV followed by placebo or TIV+placebo followed
y PCV13 at 0 and 1 month. Inﬂuenza vaccine titres and PCV13
erotype titres were measured before and 1 month after vacci-
ation. The immune response to TIV was comparable whether
t was given alone or with PCV13, based on the percentage of
ubjects with a 4-fold increase in titres for concomitant vaccine
ntigens after receiving PCV13+TIV compared with TIV+placebo
nd the percentage of subjects achieving a hemagglutination
nhibition titre ≥40 after receiving PCV13+TIV. A comparison of
neumococcal immunoglobulin G geometric mean concentrations
month after PCV13+TIV and PCV13 given alone showed that the
mmune response was comparable. Local reactions were mainly
ild and were comparable between PCV13+TIV and PCV13 alone
46.9% and46.6%, respectively). However, the incidence of systemic
eactions was higher in subjects receiving both vaccines compared
ith either vaccine alone (PCV13+TIV 60.2% vs TIV 50.7% and
CV13 48.6%).
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Expanding the options in pneumococcal immunization
A 10-valent pneumococcal polysaccharide conjugate vaccine
(PCV10) was recently licensed in Europe based on immunogenicity
comparable to the 7-valent pneumococcal conjugate vaccine
(PCV7). PCV10 contains serotypes 1, 5, and 7F, in addition to those
contained in PCV7 (4, 6B, 9V, 14, 18C, 19F, and 23F). Clinical studies
evaluating the immunogenicity of PCV10 compared with that of
PCV7 indicate that antibody levels for the common serotypes were
similar.1 Immunogenicity responses to serotypes 5 and 7F were
high, whereas responses to serotype 1 were somewhat lower.
PCV10 also induced high antibody responses against protein D. Fol-
lowing thebooster dose, almost all subjects reachedpredetermined
enzyme-linked immunosorbent assay (ELISA) and opsonophago-
cytic assay (OPA) antibody thresholds. When coadministered with
common pediatric vaccines, PCV10 was comparable to PCV7 in
terms of compatibility, with no difference in antibody responses
being observed with either pneumococcal vaccine.
PCV10 is designed to provide protection against mucosal
disease caused by Streptococcus pneumoniae, such as acute otitis
media (AOM) and pneumonia, as well as those caused by non-
typeable Haemophilus inﬂuenzae (NTHi), such as AOM. These 2
organisms account for ≥80% of bacterial AOM cases worldwide.2
In the Pneumococcal Otitis Efﬁcacy Trial (POET),2 an 11-valent
prototype vaccine was found to provide protection against AOM
caused by both S pneumoniae and NTHi, reducing conﬁrmed AOM
episodes by one third and signiﬁcantly reducing episodes caused
by NTHi by 35% (P=0.041).
A controlled safety study3 of this 11-valent vaccine was con-
ducted in 12,194 Filipino infants who received 3 doses of the
vaccine or placebo at 6, 10, and 14 weeks of age. The majority of
serious adverse events (AEs) or clinical episodes (pneumonia, gas-
troenteritis, suspected sepsis, meningitis, or other severe illness
necessitating hospital admission) occurredwithin 28 days of vacci-
nation. Therewas anexcess of seriousAEs following receipt of 1 or 2
doses of the vaccine, but not after the third dose. Acute lower respi-
ratory infections were diagnosed most often during follow-up hos-
pital investigations. The 11-valent vaccine did not appear to have
a protective effect against viral-associated lower respiratory tract
infection; interestingly, there was an excess of cytomegalovirus.4
Prymula et al5 conducted a study on the nasopharyngeal
carriage of S pneumoniae vaccine serotypes following vaccination
with PCV10. Subjects were infants primed at age 3, 4, and 5
months with PCV10 followed by a booster at 12–15 months of
age or age-matched controls who received a ﬁrst dose of the
meningococcal ACWY-TT vaccine at 12–15 months of age. Carriage
of S pneumoniae vaccine serotypes were assessed before the
meningococcal vaccination or the PCV10 booster vaccination and
at 1, 3, 7, and 12months after vaccination. Carriage of S pneumoniae
vaccine serotypes in the second year of life was reduced by 22–35%
in subjects who received PCV10, although carriage of nonvaccine
serotypes tended to increase in this group, similar to previous
experiences with the 7-valent pneumococcal conjugate vaccine.PCV10 also has been shown to be immunogenic and well
tolerated when used in the primary immunization of both pre- and
full-term infants. In an open study6 designed to evaluate immune
responses and safety of the PCV10 booster vaccination, children
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6–18 months of age who had been primed with PCV10 and
TaP-IPV/Hib vaccines received a booster dose of PCV10 coadmin-
stered with the DTaP-IPV/Hib booster. Antibodies were measured
month after the booster dose by ELISA and OPA. Robust increases
n antibody concentrations were observed following the booster
ose for all vaccine serotypes. About 98% of subjects developed
ntibody concentrations ≥0.2g/mL, and >90% developed an OPA
itre ≥8 for each of the vaccine serotypes. The most common side
ffects were pain and irritability; no serious AEs were reported
uring the active study phase.
In a Turkish study, Bakir et al7 used a steady-state, age-
ompartmental population model that simulates vaccine impact
or 1 year, as well as local demographic, epidemiologic, and cost
ata, to assess the clinical impact and cost-effectiveness of PCV10.
he model assumed an 86% vaccine coverage rate and a 4-dose
3+1) regimen. Results of the study indicate that PCV10 vaccina-
ion would be cost-effective, as it would reduce pneumococcal and
OM disease burden in Turkey with and without herd immunity
rotection. Similarly, a 1-year, cross-sectional, population-based
odel at a vaccine steady-state was used to assess the clinical
mpact and cost-effectiveness of vaccination with PCV10 or PCV7
n Mexico.8 Local health costs were used. Compared with no vacci-
ation, vaccination with PCV10 and PCV7 were predicted to reduce
neumococcus and NTHi disease burden. Both interventions were
hown to be cost-effective; however, PCV10 produced greater cost
avings and better outcomes.eferences
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